[46] The study also showed that CRVO treatment with an anti-VEGF agent used on a monthly basis for 6 months followed by PRN produces significantly better results in all end points compared with sham.

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

After hours: February 13 at 5:17:07 PM EST Loading Chart for CRVO ...

Central Oregon’s two-week bout of cold, snowy weather ramped up again on Thursday morning with a few inches of new snow around the still-very cold… ...

The antiphospholipid syndrome associated with hepatic vein thrombosis has usually been of the primary type; that is, the American Rheumatism Association criteria for the diagnosis of systemic ...

Rights Mar 17, 2011 Mar 18, 2011 Jul 29, 2010 Rights ratio: 3 share for every 5 held at a price of Rs 103.0 ...